Table 2.
Patient characteristics at baseline by treatment continuity during 24 month follow-up (n = 1,110)
| Met/Incr (n = 635) | Met/SU (n = 255) | Insulin ± any OAD (n = 220) | ||||
|---|---|---|---|---|---|---|
| Stable | Switch | Stable | Switch | Stable | Switch | |
| (n = 421; 66.3%) | (n = 214; 33.7%) | (n = 154; 60.4%) | (n = 101; 39.6%) | (n = 151; 68.6%) | (n = 69; 31.4%) | |
| Age (years) | 65.6 (57.7–73.0) | 61.6 (55.0–69.2) | 68.6 (59.6–73.2) | 64.8 (56.8–71.2) | 64.0 (54.6–72.9) | 58.8 (54.1–65.1) |
| Female gender (%) | 48.7 | 48.6 | 51.9 | 34.7 | 42.4 | 44.9 |
| Body weight (kg) | 89 (78–101) | 91 (80–104) | 87 (77–95) | 86 (79–103) | 90 (80–106) | 89 (78–98) |
| Diabetes duration (years) | 4.6 (2.1–7.6) | 4.5 (1.7–7.8) | 5.3 (2.4–8.6) | 5.0 (2.5–8.6) | 7.1 (3.6–10.7) | 5.6 (2.6–8.3) |
| Blood glucose | ||||||
| HbA1c (%) | 7.2 (6.8–7.7) | 7.4 (6.8–8.0) | 7.1 (6.7–7.9) | 7.3 (6.9–8.2) | 8.3 (7.3–9.6) | 7.9 (7.1–8.9) |
| FPG (mg/dl) | 134 (116–158) | 140 (120–165) | 135 (114–158) | 133 (117–158) | 156 (130–206) | 150 (123–182) |
| PPG (mg/dl) | 174 (146–210) | 178 (145–210) | 177 (158–207) | 169 (154–196) | 202 (171–239) | 198 (165–235) |
| Anamnestic hypoglycaemia* (%) | 2.9 | 5.1 | 4.5 | 7.9 | 19.2 | 43.5 |
| Concomitant disease (%) | ||||||
| MACCE (%) | 9.3 | 10.3 | 11.7 | 10.0 | 12.0 | 4.3 |
| Macrovasc. complication (%) | 12.9 | 16.0 | 14.3 | 14.0 | 20.0 | 8.7 |
| Microvasc. complication (%) | 12.1 | 18.7 | 10.3 | 13.9 | 23.2 | 11.6 |
Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG, fasting plasma glucose; PPG, postprandial plasma glucose; MACCE, major cardiac or cerebrovascular event; *within 12 months prior to baseline.